Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, with regard to the NHS Federated Data Platform uptake and benefits, updated on 30 October, how many of the 563,239 people removed from the waiting list were removed for the reason of (1) receiving treatment, (2) improved conditions, (3) opting for alternative care, (4) returning to general practice for primary care, (5) returning to optometry for primary care, (6) returning to pharmacy for primary care, (7) returning to primary care not otherwise specified, and (8) other reasons not otherwise specified.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Federated Data Platform’s referral to treatment validation tool supports National Health Service staff to better manage the waiting lists of patients who have been referred for non-urgent elective care.
The Department does not hold the data required to detail the breakdown of reasons patients were removed from the waiting lists as this is patient-level data which is held by trusts themselves in their electronic patient records.
Waiting list validation is a core part of providers’ management of waiting lists which involves ensuring patients’ records are accurate and up to date, that patients still want their treatment, and that they have opportunities to update their clinical team about changes in their condition or relevant circumstances.
This ensures providers have an accurate understanding of the true size of their waiting list, whilst helping minimise missed or cancelled appointments and ensuring the most effective use of clinicians’ time.
Waiting list validation is a well-established component for the effective management of waiting lists, with detailed guidance available for trusts, including safeguards to ensure patients are not incorrectly removed from waiting lists. NHS guidance states there “must be agreement from a clinician before any patient is returned to the referrer”. Any patient removed should receive a letter that would also be sent to their general practitioner.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 19 September 2024 (HL968), why the Privacy Enhancing Technology data protection impact assessment has not been published, and when they plan to publish it.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England has recently completed a substantial update to the suite of Data Protection Impact Assessments (DPIAs) relating to the Privacy Enhancing Technology (PET). These updates were necessary to ensure that the DPIAs reflect the latest technical developments and governance requirements.
These comprise: a Technical DPIA; a Local Operational DPIA; and a National Operational DPIA. NHS England is now undertaking the final stages of review and preparation to ensure that these documents meet all publication standards and accessibility requirements. It is anticipated that the updated PET DPIAs will be published in December 2025.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether a decision has been made about the platform that will host the proposed single patient record.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
No final decision has been made about how the single patient record will be delivered.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department for Science, Innovation & Technology:
To ask His Majesty's Government what assessment they have made of the implications of requiring the use of technology that does not yet exist, or function satisfactorily, in notices under section 121 of the Online Safety Act 2023.
Answered by Baroness Lloyd of Effra - Baroness in Waiting (HM Household) (Whip)
Ofcom will set out what technology is required for a service to comply with a Technology Notice under section 121 of the Online Safety Act. That technology must be accredited as meeting minimum standards of accuracy. Ofcom’s consultation on the minimum standards of accuracy closed in March 2025 and the finalised version will be published in due course.
Where a tech solution does not exist in relation to a particular service design, Ofcom will be able to direct companies to use best endeavours to develop or source technology that deals with child sexual exploitation and abuse content.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 8 October (HL10211), what recourse is available to patients for whom a 'do not resuscitate' decision was made by medical staff prior to a surgical procedure without consulting either the patient or their family.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
A Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) is a clinical decision made on the basis of a senior clinical assessment of a patient’s condition. It remains best practice to communicate this decision to the patient and if they lack capacity, their family or representative.
If the patient or their family or representative do not agree with the decision, they should be given time to ask for a second opinion or review. This is in line with the National Health Service guidance for DNACPR decisions. Guidance and information for the public on DNACPR decisions is available on the NHS website, including information on asking for a second opinion or a review and what to do if there are concerns about, or disagreement with, a DNACPR form in a patient’s or family member’s medical records.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they will publish the planned timeline for widening access to genetic risk assessment and genomic testing for cardiovascular and metabolic conditions; and if so, when.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan included a commitment to begin implementing Integrated Risk Scores that bring together polygenic risk scores and other non-biological risk factors. NHS England, in partnership with Our Future Health and clinical experts, will carry out a three year service evaluation from 2026/27.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to integrate multi-condition genetic risk scoring for high-impact conditions into the NHS prevention framework in order to achieve measurable reductions in disease prevalence and healthcare costs.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service, in partnership with Our Future Health, will trial the use of Integrated Risk Scores, which combine genomic, lifestyle, and health data, within the newly announced neighbourhood health services. Initially focused on cardiovascular disease and diabetes, the programme will expand to includes breast, bowel, and prostate cancer, with other diseases such as glaucoma, osteoporosis, and dementia under consideration. This marks a major step toward routine genetic testing in preventive care, enabling earlier and more personalised interventions.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what specific actions and policies they are considering to help families with genetic risk profiles across chronic conditions, such as type 1 and type 2 diabetes and cardiovascular disease, to be proactive in managing their conditions.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Health Service, in partnership with Our Future Health, will trial the use of Integrated Risk Scores, which combine genomic, lifestyle, and health data, within the newly announced neighbourhood health services. Initially focused on cardiovascular disease and diabetes, the programme will expand to includes breast, bowel, and prostate cancer, with other diseases such as glaucoma, osteoporosis, and dementia under consideration. This marks a major step toward routine genetic testing in preventive care, enabling earlier and more personalised interventions.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to position the United Kingdom as a global leader in the use of newborn genetic screening data to support earlier detection and prevention of conditions, including diabetes, neurological disorders and rare genetic diseases.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
As set out in the 10-Year Health Plan, the Government has an ambition to offer newborn genomic testing as part of routine National Health Service care within the next decade. The Generation Study is developing evidence to inform this ambition, by evaluating the effectiveness of using whole genome sequencing to test 100,000 newborns for over 200 genetic conditions. Positive results are only returned where there is robust evidence that a treatable condition is likely to develop within the first five years of life. There are no plans to screen for conditions that appear later in life or remain asymptomatic. By summer 2027, 100,000 newborns will have had their whole genomes sequenced. The evaluation part of the study will then be completed and presented to the UK National Screening Committee (UK NSC). Subject to the study’s evaluation, the UK NSC’s advice, and the appropriate funding, genomic testing could be available for all newborns in the United Kingdom by 2035.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many yellow card reports of increased sexual arousal (Medical Dictionary for Regulatory Activities code 10021679) the Medicines and Healthcare products Regulatory Agency received each year since 2014, and what medications those reports were tied to.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
A total of 52 reports that describe increased sexual arousal suspected to be associated with the use of medicines or vaccines have been received through the Yellow Card scheme. The reports were received between 2014 and 2025 for a wide range of medicinal products which include antidepressants, hormonal medicines, vaccines, antipsychotics, antibiotics, cardiovascular medicines, drugs used to treat attention deficit hyperactivity disorder, sedatives, drugs used to treat dementia and diabetes, and single reports for drugs used to treat osteoporosis, Parkinson’s disease, and pain.
The term increased sexual arousal itself is not in the product information for any of the above classes of medicines, however terms such as increased libido and hypersexuality are reflected in product information for medicines used to treat Parkinson’s disease. The following table shows a breakdown of all spontaneous Yellow Card Reports the Medicines and Healthcare products Regulatory Agency (MHRA) received from 1 January 2014 to 4 November 2025, where the MedDRA, a categorisation of medical terminology, Lowest Level Term (LTT) ‘increased sexual arousal’ was reported:
Year | Number of reports |
2014 | 1 |
2015 | 1 |
2016 | 6 |
2017 | 4 |
2018 | 1 |
2019 | 4 |
2020 | 6 |
2021 | 14 |
2022 | 5 |
2023 | 4 |
2024 | 1 |
2025 | 5 |
of | 52 |
In addition, the following able shows a breakdown of all spontaneous Yellow Card Reports the MHRA received from 1 January 2014 to 4 November 2025 where the MedDRA LLT ‘increased sexual arousal’ was reported, broken down by substance:
Year | Substance | Number of reports |
2014 | TRAZODONE | 1 |
2015 | CITALOPRAM | 1 |
PROPRANOLOL | 1 | |
2016 | AMOXYCILLIN | 1 |
ARIPIPRAZOLE | 1 | |
CLAVULANIC ACID | 1 | |
ETHINYLESTRADIOL | 1 | |
FLUPENTHIXOL | 1 | |
METRONIDAZOLE | 1 | |
NORELGESTROMIN | 1 | |
SERTRALINE | 2 | |
SOLIFENACIN | 1 | |
2017 | CITALOPRAM | 2 |
MEMANTINE | 1 | |
SERTRALINE | 1 | |
2018 | SERTRALINE | 1 |
2019 | FLUOXETINE | 1 |
LISDEXAMFETAMINE | 1 | |
METHYLPHENIDATE | 1 | |
SERTRALINE | 1 | |
2020 | CANDESARTAN | 1 |
DULOXETINE | 1 | |
ETHINYLESTRADIOL | 1 | |
LEVONORGESTREL | 1 | |
LISINOPRIL | 1 | |
RISPERIDONE | 1 | |
TERIPARATIDE | 1 | |
ULIPRISTAL | 1 | |
VENLAFAXINE | 1 | |
2021 | ARIPIPRAZOLE | 1 |
ChAdOx1 nCoV-19 | 2 | |
CIPROFLOXACIN | 1 | |
CITALOPRAM | 2 | |
ESTRADIOL | 1 | |
FLUCLOXACILLIN | 1 | |
OESTRIOL | 1 | |
PAROXETINE | 1 | |
SERTRALINE | 2 | |
TOZINAMERAN | 2 | |
TRAZODONE | 1 | |
2022 | ARIPIPRAZOLE | 1 |
DONEPEZIL | 1 | |
ELASOMERAN | 1 | |
OESTRIOL | 1 | |
TOZINAMERAN | 1 | |
2023 | DIAZEPAM | 1 |
DOXYCYCLINE | 1 | |
LISDEXAMFETAMINE | 1 | |
MEMANTINE | 1 | |
2024 | CLONAZEPAM | 1 |
2025 | ARIPIPRAZOLE | 1 |
FLUOXETINE | 1 | |
LINAGLIPTIN | 1 | |
PRAMIPEXOLE | 1 | |
TIRZEPATIDE | 1 |